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Introduction
Little is known about survival and trafficking of ex vivo
expanded dendritic cells (eDCs) after adoptive transfer in
animals. We investigated the trafficking patterns of eDCs
in mice that had received allogeneic BMT.
Methods
C57BL/6 (H2b) BM was depleted of B220+, CD3+ and
GR1+ cells and was expanded for 7 days with GM-CSF, IL-
4 and Flt3L. A retroviral vector encoding for luciferase
(luc) and gfp was used for transduction. EDCs were ana-
lyzed by FACS and functionality was tested with MLR.
EDCs from C57BL/6 donor mice were injected i.v. at 4 ×
106 per animal into BALB/c recipients that had received
either allogeneic myeloablative BMT (BALB/c-mbl) or
non-myeloablative BMT (BALB/c-n/mbl) conditioning.
Survival and in vivo trafficking of gfp/luc+ eDCs were mon-
itored by bioluminescent imaging (BLI). Tissues were
examined for gfp+ eDCs using immunofluorescence
microscopy. Additional experiments were performed with
eDCs generated from gfp-transgeneic animals (C57BL/6-
TgN(ActbEGFP)1OSB, H2b).
Results
Expansion of depleted BM with GM-CSF, IL4 and FLT3L
induced a polyclonal population of CD11c+CD11b+ and
CD11c-CD11b+ eDCs. Both populations expressed CD40,
CD80, CD86 and MHC II. No CD3+ or NK1.1+ cells were
found, the number of CD19+ cells ranged from 0–2.5%.
After transduction, gfp+ cells represented up to 36% of via-
ble cells. EDCs were functional in a MLR assay. After injec-
tion, transduced cells were monitored in vivo with BLI for
up to 100 days. In BALB/c-mbl and BALB/c-n/mbl eDCs
were initially detected in the area of the lungs and later in
the area of the gut, spleen and thymus. Using immunoflu-
orescence microscopy, gfp/luc+ eDCs and gfp-transgenic
eDCs were detected at different time points in the spleen,
Peyers patches, thymus and lymph nodes. During the
observation period no animal exhibited signs of GvHD.
Conclusion
Here, we show that donor-derived, ex vivo expanded DCs
survive in hosts after allogeneic, MHC mismatched BMT
for at least 6 weeks. EDCs migrate to lymphoid organs like
spleen, Peyers patches, lymph nodes and thymus. Myelo-
ablative or non-myeloablative conditioning does not sig-
nificantly affect trafficking patterns. Mice that had
received eDCs developed no clinical signs of GVHD. The
ability to visualize DC survival and trafficking gives new
insight into the biology of adoptively transferred DCs and
will help to optimize DC based treatment strategies.
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